Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
MK-1484 / Merck (MSD)
MK-1484-001, NCT05382325: A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors	Active, not recruiting	1	70	Europe, Canada, US, RoW	MK-1484, SP'482, Pembrolizumab, MK-3475, Keytruda®	Merck Sharp & Dohme LLC	Advanced or Metastatic Solid Tumors	07/26	07/26